The neoadjuvant regimen of nivolumab combined with gemcitabine and cisplatin achieved a pathologic nonmuscle-invasive rate of 66% and a pathologic complete response rate of 49% in patients with muscle-invasive bladder cancer.
Original Article: Nivolumab Neoadjuvant Regimen Nears 50% pCR in MIBC